Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cangrelor

FDA-approved product (powder, intravenous), marketed as Cangrelor, Kengreal.

Registered studies
45
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cangrelor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Myocardial infarction
  • Percutaneous Coronary Intervention
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
P2Y12 Platelet Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cangrelor in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cangrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia

    NCT07817680 · start 2026-11-01

    Registered record
    Registry ID
    NCT07817680
    Conditions
    Heparin-induced Thrombocytopenia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2028-02-01
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-induced Thrombocytopenia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • The Bridging Antiplatelet Therapy With Cangrelor 2 Study

    NCT07225842 · start 2026-02-18

    Registered record
    Registry ID
    NCT07225842
    Conditions
    Coronary Arterial Disease (CAD)
    Interventions
    Cangrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-18
    Completion
    2027-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Arterial Disease (CAD)
    InterventionCangrelor
    PhasePhase 4
    Registry statusRecruiting

  • Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

    NCT07514962 · start 2024-05-12

    Registered record
    Registry ID
    NCT07514962
    Conditions
    Coronary Artery Disease; Antiplatelet Therapy; Minimally Invasive Coronary Revascularization Surgery
    Interventions
    Cangrelor-guided MIDCAB surgery (for the prospective cases); Aspirin MIDCAB surgery (for the historical controls)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-05-12
    Completion
    2028-01-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Antiplatelet Therapy; Minimally Invasive Coronary Revascularization Surgery
    InterventionCangrelor-guided MIDCAB surgery (for the prospective cases); Aspirin MIDCAB surgery (for the historical controls)
    PhaseNot recorded
    Registry statusRecruiting

  • Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

    NCT05611242 · start 2024-05-08

    Registered record
    Registry ID
    NCT05611242
    Conditions
    Acute Ischemic Stroke
    Interventions
    MT+CAS with IV-AP; MT+CAS with PO-AP; MT+CAT with PO-AP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-05-08
    Completion
    2027-05-08
    Enrolment
    404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionMT+CAS with IV-AP; MT+CAS with PO-AP; MT+CAT with PO-AP
    PhasePhase 3
    Registry statusRecruiting

  • Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO

    NCT06792643 · start 2024-04-01

    Registered record
    Registry ID
    NCT06792643
    Conditions
    Cardiogenic Shock; Extracorporeal Membrane Oxygenation Complication; Platelet Dysfunction
    Interventions
    Cangrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-01
    Completion
    2025-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiogenic Shock; Extracorporeal Membrane Oxygenation Complication; Platelet Dysfunction
    InterventionCangrelor
    PhasePhase 2
    Registry statusRecruiting

  • Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention

    NCT06089577 · start 2023-11-01

    Registered record
    Registry ID
    NCT06089577
    Conditions
    Coronary Artery Disease
    Interventions
    Cangrelor 50 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-11-01
    Completion
    2026-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionCangrelor 50 MG
    PhasePhase 4
    Registry statusRecruiting

  • in Patients With SCAD Undergoing Complex PCI, the RESPONSE Study"

    NCT04251039 · start 2022-12

    Registered record
    Registry ID
    NCT04251039
    Conditions
    Coronary Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-12
    Completion
    2023-12
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry

    NCT05505591 · start 2022-06-06

    Registered record
    Registry ID
    NCT05505591
    Conditions
    Bleeding; Coronary Artery Disease; Myocardial Infarction
    Interventions
    Cangrelor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-06-06
    Completion
    2022-10-31
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBleeding; Coronary Artery Disease; Myocardial Infarction
    InterventionCangrelor
    PhaseNot recorded
    Registry statusUnknown

  • Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

    NCT05193019 · start 2022-03-14

    Registered record
    Registry ID
    NCT05193019
    Conditions
    Ischemic Heart Disease; Acute Coronary Syndrome
    Interventions
    Parenteral antiplatelet agents
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-03-14
    Completion
    2026-06-01
    Enrolment
    717

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Heart Disease; Acute Coronary Syndrome
    InterventionParenteral antiplatelet agents
    PhaseNot recorded
    Registry statusActive not recruiting

  • REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

    NCT04667078 · start 2022-03-02

    Registered record
    Registry ID
    NCT04667078
    Conditions
    Acute Ischemia
    Interventions
    Cangrelor; best medical management
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-03-02
    Completion
    2030-09-01
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemia
    InterventionCangrelor; best medical management
    PhasePhase 3
    Registry statusRecruiting

  • Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

    NCT04927949 · start 2021-06-08

    Registered record
    Registry ID
    NCT04927949
    Conditions
    ST-elevation Myocardial Infarction
    Interventions
    cangrelor perfusion during PCI; standard PCI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-08
    Completion
    2023-03-31
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST-elevation Myocardial Infarction
    Interventioncangrelor perfusion during PCI; standard PCI
    PhasePhase 4
    Registry statusCompleted

  • Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock

    NCT04611607 · start 2021-05-04

    Registered record
    Registry ID
    NCT04611607
    Conditions
    Acute Myocardial Infarction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-05-04
    Completion
    2022-06-07
    Enrolment
    303

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)

    NCT04790032 · start 2021-03-16

    Registered record
    Registry ID
    NCT04790032
    Conditions
    Percutaneous Coronary Intervention
    Interventions
    Cangrelor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-16
    Completion
    2024-07-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPercutaneous Coronary Intervention
    InterventionCangrelor
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

    NCT04668144 · start 2021-02-18

    Registered record
    Registry ID
    NCT04668144
    Conditions
    Coronary Artery Disease; Acute Coronary Syndrome
    Interventions
    Cangrelor; Prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-02-18
    Completion
    2023-05-11
    Enrolment
    359

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Acute Coronary Syndrome
    InterventionCangrelor; Prasugrel
    PhasePhase 4
    Registry statusCompleted

  • PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

    NCT04634162 · start 2021-02-09

    Registered record
    Registry ID
    NCT04634162
    Conditions
    Coronary Artery Disease
    Interventions
    Cangrelor; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-02-09
    Completion
    2021-11-30
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionCangrelor; Placebo
    PhasePhase 4
    Registry statusCompleted